The prolonged COVID-19
has increased the importance of virus research worldwide. We have been affected
by many viruses. Colds, which are now simply recognized, are also viruses.
However, the perception of the virus is changing as we go through COVID-19, and
the state's inability to play its role due to infectious diseases that have
never been experienced has shocked everyone.
As such, research on
viruses or diseases should continue, and facility investment and strengthening
research talent are the same as tasks that the government should take the lead
in. Studies are continuing to prepare for such viruses and diseases in Korea.
NKCL Bio Group is a
company that has been recognized for its value as it enters the COVID-19 era.
Let’s meet NKCL Bio Group, a bio company specializing in immune cell therapy, with
Shin Dong-hwa, CEO of the group.
What kind of company
is the NKCL Bio Group?
NKCL Bio Group is a
bio-specialized company that aims to provide a personalized immune care
platform service based on NK Cell with abundant clinical experience and
know-how by studying its own cell culture technology and cell therapy over the
past decade.
NK Cell is a natural
killer cell, which is responsible for the most important immune system in our
body, and its importance has begun to be recognized again as social interest in
immune care has emerged due to the COVID-19 pandemic.
The group's culture
technology has a much higher cell culture yield than the existing culture
technology, and has been making independent and unrivaled moves by establishing
an automatic GMP culture system capable of mass production of NK Cell and
researching NK cell therapy to lead the market.
About the main
business
We are developing a
variety of products for improving immunity and treating various diseases and
anticancer drugs. But prevention is more important than treatment. As the
average life expectancy of modern people increases, immunity is important to
live a healthier and more energetic life in senior age.
Accordingly, NKCL has
developed and released various products and services such as NK Immune Water
(deep ocean water), NK Blue Bio Cream (functional cosmetics series), NK
Cordycep Gold 300 (food contributing to immunity and anticancer effects), and
NK Immune Bakery (immune bread) that can strengthen the immune system in daily
life.
Among the various
products introduced by the company, cosmetics have anti-inflammatory and
antibacterial functions as well as regeneration by adding NK cell culture
solutions, which help the elderly regenerate their skin and improve their
troubles. In addition, it is effective in atopic dermatitis and psoriasis.
In addition, NKCL's own
NK Cell culture technologies were registered as intellectual property rights,
and the GMP automatic culture system with artificial intelligence found its own
culture environment optimized for NK cell culture and increased its maximum
production per day. In addition, it has the advantage of being able to block
concerns about human errors and technology leaks.
Recently, the
preclinical stage of RK-NKTM cell therapy has been completed, making progress
in the immune care business. The RK-NKTM cell therapy preclinical trial
conducted repeated toxicity and recovery experiments for six weeks at the
Ministry of Food and Drug Safety's clinical trial certified institution for
human-derived breast, lung, liver, and kidney cancer cell lines transplanted
into nude mice. As a result, it was confirmed that NK immune cells activated by
culturing with RK-NKTM Kit were secured to be non-toxic, and the possibility of
being a treatment that can effectively control cancer cells was proved.
The company is
attracting attention as a representative of Korean immune brands in response to
the rapidly changing era, creating more than 300% of jobs compared to the
previous year by expanding production facilities of the GMP automatic culture
system in 2022, and expects to create more than 1,000% in 2023.
Lastly, if you have
a goal please?
The company aims to
enter the global market by developing differentiated products in these cell
therapy products markets. To this end, it is establishing a close cooperative
system with various universities and domestic cooperative hospitals, including
Hanyang University's ERICA Campus and Hanyang Institute for Precision
Therapeutics(HY-IPT), for research and clinical research on cell therapy.
In addition, the
introduction of an automatic cell culture system greatly reduces labor costs
and production costs, so it is expected to contribute to the realization of
mass production and popularization of NK cell therapy by reducing treatment
prices.